{
    "nct_id": "NCT02855944",
    "official_title": "ARIEL4 (Assessment of Rucaparib In Ovarian CancEr TriaL): A Phase 3 Multicenter, Randomized Study of Rucaparib Versus Chemotherapy in Patients With Relapsed, BRCA Mutant, High Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",
    "inclusion_criteria": "* Be 18 years of age at the time the informed consent form is signed\n* Have a histologically confirmed diagnosis of high-grade serous or Grade 2 or Grade 3 endometrioid epithelial ovarian, fallopian tube, or primary peritoneal cancer\n* Received â‰¥ 2 prior chemotherapy regimens and have relapsed or progressive disease as confirmed by radiologic assessment\n* Have biopsiable and evaluable disease. Note: biopsy is optional for patients known to harbor a BRCA1/2 mutation\n* Have sufficient archival formalin-fixed paraffin-embedded (FFPE) tumor tissue available for planned analyses\nHealthy volunteers allowed\nMust be FEMALE\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* History of prior cancers except for those that have been curatively treated, with no evidence of cancer currently (provided all chemotherapy was completed >6 months prior and/or bone marrow transplant >2 years prior to first dose of rucaparib).\n* Prior treatment with any PARP inhibitor\n* Symptomatic and/or untreated central nervous system metastases\n* Pre-existing duodenal stent and/or any other gastrointestinal disorder or defect that would, in the opinion of the Investigator, interfere with absorption of rucaparib\n* Women who are pregnant or breast feeding\n* Hospitalization for bowel obstruction within 3 months prior to enrollment",
    "miscellaneous_criteria": ""
}